Delcath Systems Under StockCall Microscope: Will This Drug Delivery System's Stocks Rebound This Year? PR Newswire LONDON, January 30, 2013 LONDON, January 30, 2013 /PRNewswire/ -- The pharmaceutical sector is a cost intensive sector and its R&D expenses are formidable. However, despite the high costs involved, there are a large number of small companies trying to innovate in this field. While, this is good news for patients, the investors are generally left high and dry until these companies receive requisite regulatory approvals for their products. Point in case is Delcath Systems Inc. (NASDAQ: DCTH) which is waiting for limited marketing approval for its chemotherapy drug delivery system Chemostat. The StockCall review of Delcath Systems provides a wide-ranging technical analysis about the company. Sign up today and read the free report at http://www.stockcall.com/registration Delcath Seeks Limited Marketing Approval for Chemostat Delcath Systems' fortunes hinge on its cancer drug delivery systems. Its Chemostat system is designed for administering chemotherapy for liver cancer. The product was sent to the FDA for approval in August, 2012. However, its application process has been fraught with obstacles. It was denied preferential track and later the company itself decided to seek more limited marketing approval for the system. While the FDA decision is expected by June of this year, the prospects do not look very promising. The system was earlier denied approval in 2010, but it is already approved in Europe. Register today to access the free report on Delcath Systems at http://www.StockCall.com/DCTH012913.pdf Taking the best case scenario, the company expects to start marketing the new system during the fourth quarter of this year. As per its revised application, the system will be marketed for ocular melanoma only. Delcath - Strategic Step and Limited Upside Delcath is also augmenting its financial position. The company recently inked a deal with Terrapin Opportunity LP. Under this deal, Terrapin agreed to acquire up to $35 million worth of company stock within the next two years. The arrangement will provide Delcath with financial flexibility. Delcath stock has been in free fall for the past year and the trend is likely to continue. With the company looking for limited approval for Chemostat, the chances of stock going up have also been considerably muted. Even in the most optimistic scenario of Chemostat getting the FDA approval, the upside to the stock is rather limited. About StockCall.com StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com Contact: William T. Knight, Email: firstname.lastname@example.org, Contact Number: +1(646)-396-9857 (9:00 am EST - 01:30 pm EST)
Delcath Systems Under StockCall Microscope: Will This Drug Delivery System's Stocks Rebound This Year?